Albuminuria: Its importance in disease detection

Laboratory Medicine

Volumn 38, Issue 1, 2007, Pages 35-38

  Clavant, Steven P ^a,b   Osicka, Tanya M ^a,b   Comper, Wayne D ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Accumin Diagnostics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58149472206     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/972N441WGKPRTMRK     Document Type: Review

References (59)

1. American Diabetes Association. Diabetic nephropathy. Diabetes Care. 2003;26:S94-S98.
2. The ATLANTIS Study Group. Low dose ramipril reduces albuminuria in type 1 diabetic patients without hypertension. Diabetes Care. 2000;23:1823-1829.
3. Parving H-H, Lehnert H, Bröchner-Motensen J, et al. Irbesartan in patients with type 2 diabetes and microalbuminuria study group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345:870-878.
4. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
5. Mogensen CE. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Intern Med. 2003;254:45-66.
6. Gerstein HC, Mann JF, Yi Q, et al. HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. J Am Med Assoc. 2001;286:421-426.
7. Hillege HL, Fidler V, Diercks GF, et al. Prevention of renal and vascular end stage disease (PREVEND) study group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777-1782.
8. Romundstad S, Holmen J, Kvenild K, et al. Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals a 4.4-year follow-up study. Am J Kidney Dis. 2003;42:466-473.
9. Gerstein HC, Mann JF, Pogue J, et al. Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. Diabetes Care. 2000;23(Suppl 2):B35-B39.
10. Rossa TT, Palatini P. Clinical value of microalbuminuria in hypertension. J Hypertens. 2000;18:645-654.
11. Bigazzi R, Bianchi S, Campese VM, et al. Prevalence of microalbuminuria in a large population of patients with mild to moderate essential hypertension. Nephron. 1992;61:94-97.
12. Agrawal B, Berger A, Wolf K, et al. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens. 1996;14:223-228.
13. Agewall S, Persson B, Samuelsson O, et al. Microalbuminuria in treated hypertensive men at high risk of coronary disease. J Hypertens. 1993;11:461-469.
14. Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE study. Ann Intern Med. 2003;139:901-906.
15. Deferrari G, Repetto M, Calvi C, et al. Diabetic nephropathy from micro- to macroalbuminuria. Nephrol Dial Transplant. 1998;13:11-15.
16. Marshall SM, Alberti KG. Comparison of the prevalence and associated features of abnormal albumin excretion in insulin-dependent and non-insulin-dependent diabetes. Q J Med. 1989;70:61-71.
17. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310:356-360.
18. Viberti GC, Hill RD, Jarrett RJ, et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet. 1982;1:1430-1432.
19. Weir MR. Microalbuminuria in type 2 diabetes: An important, overlooked cardiovascular risk factor. J Clin Hypertens. 2004;6:134-143.
20. Rossing P, Hougaard P, Borch-Johnsen K, et al. Predictors of mortality in IDDM: 10 year observational follow-up study. BMJ. 1996;313:779-784.
21. Tuomilehto J, Borch-Johnsen K, Molarius A, et al. Incidence of cardiovascular disease in type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy in Finland. Diabetologia. 1998;41:784-790.
22. Marshall SM. Blood pressure control, microalbuminuria and cardiovascular risk in type 2 diabetes mellitus. Diabet Med. 1999;16:358-372.
23. Jones CA, Francis ME, Eberhardt MS, et al. Microalbuminuria in the US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2002;39:445-459.
24. Greive KA, Balazs ND, Comper WD. Protein fragments in urine have been considerably underestimated by various protein assays. Clin Chem. 2001;47:1717-1719.
25. Gudehithlu KP, Pegoraro AA, Dunea G, et al. Degradation of albumin by the renal proximal tubule cells and the subsequent fate of its fragments. Kidney Int. 2004;65:2113-2122.
26. Osicka TM, Comper WD. Glomerular charge selectivity for anionic and neutral horseradish peroxidase. Kidney Int. 1995;47:1630-1637.
27. Osicka TM, Pratt LM, Comper WD. Glomerular capillary wall permeability to albumin and horseradish peroxidase. Nephrology. 1996;2:199-212.
28. Burne MJ, Panagiotopoulos S, Jerums G, et al. Alterations in renal degradation of albumin in early experimental diabetes in the rat: A new factor in the mechanism of albuminuria. Clin Sci. 1998;95:67-72.
29. Greive KA, Nikolic-Paterson DJ, Guimaraes MAM, et al. Glomerular permselectivity factors are not responsible for the increase in fractional clearance of albumin in rat glomerulonephritis. Am J Pathol. 2001;159:1159-1170.
30. Osicka TM, Comper WD. Protein degradation during renal passage in normal kidneys is inhibited in experimental albuminuria. Clin Sci. 1997;93:65-72.
31. Guimarães MAM, Nikolovski J, Pratt LM, et al. Anomalous fractional clearance of negatively charged Ficoll relative to uncharged Ficoll. Am J Physiol. 2003;285:F1118-F1124.
32. Schaeffer RC Jr, Gratrix ML, Mucha DR, et al. The rat glomerular filtration barrier does not show negative charge selectivity. Microcirculation. 2002;9:329-342.
33. Eppel GA, Osicka TM, Pratt LM, et al. The return of glomerular filtered albumin to the rat renal vein. Kidney Int. 1999;55:1861-1870.
34. Curtis GH, Gall DG. Macromolecular transport by rat gastric mucosa. Am J Physiol. 1992;262:G1033-G1040.
35. Hardin JA, Kimm MH, Wirasinghe M, et al. Macromolecular transport across the rabbit proximal and distal colon. Gut. 1999;44:218-225.
36. Michel CC, Curry FE. Microvascular permeability. Physiol Rev. 1999;79:703-761.
37. Rosengren B-I, Rayyes OA, Rippe B. Transendothelial transport of low-density lipoprotein and albumin across the rat peritoneum in vivo: Effects of the transcytosis inhibitors NEM and filipin. J Vasc Res. 2002;39:230-237.
38. Ghitescu L, Bendayan M. Transendothelial transport of serum albumin: A quantitative immunocytochemical study. J Cell Biol. 1992;117:745-755.
39. Ghitescu L, Fixman A, Simionescu M, et al. Specific binding sites for albumin restricted to plasmalemmal vesicles of continuous capillary endothelium: Receptor-mediated transcytosis. J Cell Biol. 1986;102:1304-1311.
40. Osicka TM, Houlihan CA, Chan JG, et al. Albuminuria in patients with type 1 diabetes is directly linked to changes in the lysosome-mediated degradation of albumin during renal passage. Diabetes. 2000;49:1579-1584.
41. Osicka TM, Strong KJ, Nikolic-Paterson DJ, et al. Renal processing of serum proteins in an albumin-deficient environment: An in vivo study of glomerulonephritis in the Nagase analbuminaemic rat. Nephrol Dial Transplant. 2004;19:320-328.
42. Russo LM, Bakris G, Comper WD. Renal handling of albumin. A critical review of basic concepts and perspective. Am J Kidney Dis. 2002;39:899-919.
43. Hilliard LM, Osicka TM, Clavant SP, et al. Characterisation of the urinary degradation pathway in the isolated perfused rat kidney. J Lab Clin Med. 2006;147:36-44.
44. Osicka TM, Hankin AR, Comper WD. Puromycin aminonucleoside nephrosis results in a marked increase in fractional clearance of albumin. Am J Physiol. 1999;277:F139-F145.
45. Russo LM, Comper WD, Osicka TM. Mechanism of albuminuria associated with cardiovascular disease and kidney disease. Kidney Int. 2004;Suppl 92:S67-S68.
46. Greive KA, Eppel GA, Reeve S, et al. Immuno-unreactive albumin excretion increases in streptozotocin diabetic rats. Am J Kidney Dis. 2001;38:144-152.
47. Comper WD, Osicka TM, Jerums G. High prevalence of immuno-unreactive intact albumin in urine of diabetic patients. Am J Kidney Dis. 2003;41:336-342.
48. Comper WD, Osicka TM, Clark M, et al. Earlier detection of micro-albuminuria in diabetic patients using a new urinary albumin assay. Kidney Int. 2004;65:1850-1855.
49. Nakayama A, Ida T, Hatano Y, et al. Presence of immunounreactive albumin in the urine of diabetic patients. J Clin Lab Anal. 2006;20:29-36.
50. Osicka TM, Comper WD. Characterization of immuno-unreactive urinary albumin. Clin Chem. 2004;50:2286-2291.
51. Giampietro O, Penno G, Clerico A, et al. Which method for quantifying "microalbuminuria" in diabetics? Comparison of several immunological methods (immunoturbidimetric assay, immunonephelometric assay, radioimmunoassay and two semiquantitative tests) for measurement of albumin in urine. Acta Diabetol. 1992;28:239-245.
52. Osberg I, Chase HP, Garg SK, et al. Effects of storage time and temperature on measurement of small concentrations of albumin in urine. Clin Chem. 1990;36:1428-1430.
53. Eppel GA, Nagy S, Jenkins MA, et al. Variability of standard clinical protein assays in the analysis of a model urine solution of fragmented albumin. Clin Biochem. 2000;33:487-494.
54. Wittke S, Fliser D, Haubitz M, et al. Determination of peptides and proteins in human urine with capillary electrophoresis-mass spectrometry, a suitable tool for the establishment of new diagnostic markers. J Chromatography. 2003;1013:173-181.
55. Weissinger EM, Wittke S, Kaiser T, et al. Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int. 2004;65:2426-2434.
56. Comper WD, Jerums G, Osicka TM. Deficiency in the detection of microalbuminuria by urinary dipstick in diabetic patients. Diabetes Care. 2003;26:3195-3196.
57. Comper WD, Jerums G, Osicka TM. Differences in urinary albumin detected by four immunoassays and high performance liquid chromatography. Clin Biochem. 2004;37:105-111.
58. Brinkman JW, Bakker SJ, Gansevoort RT, et al. Which method for quantifying urinary albumin excretion gives what outcome? A comparison of immunonephelometry with HPLC. Kidney Int. 2004;92:S69-S75.
59. Polkinghorne KR, Su Q, Chadban SJ, et al. Population prevalence of albuminuria in the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study: Immunonephelometry compared with high-performance liquid chromatography. Am J Kidney Dis. 2006;47:604-613.